QX013N

QX013N is a humanized IgG1 monoclonal antibody that specifically targets c-Kit (also known as the stem cell growth factor receptor), a type III receptor tyrosine kinase. By binding to c-Kit, QX013N inhibits the differentiation, maturation, survival, proliferation, and degranulation of mast cells. This results in the reduction and depletion of mast cells and is intended for the treatment of mast cell-driven diseases such as chronic spontaneous urticaria (CSU). It is being developed by Qyuns Therapeutics and represents China's first biologic drug candidate targeting c-Kit. The drug is currently in Phase 1 clinical trials for CSU[1][2][4][5][6].